dx 9065a has been researched along with Arteriosclerosis, Coronary in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doggrell, SA | 1 |
| Alexander, J; Becker, RC; Dyke, CK; Harrington, RA | 1 |
| Becker, RC | 1 |
| Alexander, JH; Armstrong, PW; Becker, RC; Berger, PB; Bovill, EG; Burton, JR; Cohen, EA; Dyke, CK; Goodman, S; Harrington, RA; Hochman, JS; Kawai, C; Kleiman, NS; Kodama, K; Lincoff, AM; Yang, H | 1 |
| Alexander, JH; Becker, RC; Bovill, EG; Dyke, C; Harrington, RA; Hasselblad, V; Huang, Y; Saint-Jacques, H | 1 |
3 review(s) available for dx 9065a and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease?
Topics: Amidines; Coronary Artery Disease; Cyclic N-Oxides; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Naphthalenes; Propionates; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2011 |
Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
Topics: Animals; Anticoagulants; Area Under Curve; Blood Coagulation; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Humans; International Normalized Ratio; Mice; Models, Biological; Models, Chemical; Naphthalenes; Pilot Projects; Platelet Aggregation Inhibitors; Propionates; Rats; Thrombin; Thromboplastin; Thrombosis; Time Factors | 2004 |
Novel constructs for thrombin inhibition.
Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Coronary Artery Disease; Drug Design; Endothelium, Vascular; Factor Xa Inhibitors; Heparin; Humans; Naphthalenes; Polysaccharides; Prodrugs; Propionates; Stem Cell Transplantation; Thrombin; Thrombosis | 2005 |
2 trial(s) available for dx 9065a and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Coronary Artery Disease; Dose-Response Relationship, Drug; Electrocardiography; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Naphthalenes; Partial Thromboplastin Time; Propionates; Serine Endopeptidases | 2005 |
Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.
Topics: Aged; Anticoagulants; Antithrombin III; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Naphthalenes; Propionates; Thrombin | 2006 |